Drug shortage early warning, explained.

What drug shortage early warning is: seeing a supply gap while there is time to close it

One German pen, from a supplier's email to a decision about the regulator

1. An event happensA hold, a late batch, a warm truck, a tender. In the example, a sub-supplier's furnace repair cuts the glass barrels for lot 2614.
2. Someone reads it and moves the datesThe event is matched to a lot, a pack and a market, and the forecast is rebuilt with that stock taken out. This step, and the next, are what this guide is about.
3. The risk gets a date and an ownerA projected date when stock falls below the safety level, and a date when it runs out. In the example, November 30, 54 days away.
4. People choose what to doMove stock, speed a release, fly a batch, phase deliveries. One person signs, and a second signs off on a large move.
5. The regulator hears, if the law says soRegulatory affairs decides and files. The decision and its reason stay on the record, whichever way it goes.

The companies, people and figures in this example are fictional.

Why five business days is the fallback, and three more shortage surprises

Four terms shortage teams use every day

You will also see CMO (contract manufacturing organization, a firm that makes product for you), API (active pharmaceutical ingredient, the substance that does the medical work), S&OP (sales and operations planning, the regular meeting where supply and demand are reconciled) QA (quality assurance, the team that releases batches) and Tier (the priority a company gives a product on its critical list, with Tier 1 the most critical).

Why FDA reports 93 ongoing drug shortages while pharmacists report 227

In shortBoth numbers are correct for what they count. Each tracker uses its own inclusion rules, and FDA's follows a legal definition. For a manufacturer the useful figures sit lower down: FDA received 1,424 notifications in 2025 and says it helped prevent 330 shortages. Early notice is the mechanism FDA credits.

"How many drugs are in shortage?" has at least three published answers. FDA had 93 ongoing shortages at December 31, 2025.4 United States Pharmacopeia (USP), working from FDA's list, reported 75 at the same date.5

The American Society of Health-System Pharmacists (ASHP) and the University of Utah counted 227 active shortages at the end of the second quarter of 2026, the third quarterly rise in a row, against an all-time high of 323 in the first quarter of 2024.6 We read these pharmacist figures in trade press accounts, not in ASHP's or USP's own reports.

The legal definition explains part of the gap. Under FDA's rules a shortage is a period when demand or projected demand for a drug in the United States exceeds its supply.1 A hospital pharmacist who cannot buy one presentation from a usual wholesaler has a real problem that may not meet that test nationally. Read each count as an answer to its own question.

New shortages falling so far says less than it seems to. Old ones are staying. FDA's ongoing count sat at 41 in 2017 and at 93 in 2025, and FDA puts that down to market conditions, including weak incentives to make older, less profitable products and limited manufacturing capacity.4 USP's rising average duration tells the same story.5

What FDA's 2025 shortage numbers say about early notice

In 2025, 167 manufacturers told FDA about 1,424 potential shortage situations under section 506C. FDA says it helped prevent 330 shortages that year, using tools such as regulatory flexibility, and it expedited review of 224 submissions and prioritized 10 inspections.4 FDA's stated reading is that early notification requirements are helping to reduce the threat and impact of shortages.4 That is the agency's own assessment of its own program, and a prevented shortage cannot be counted as cleanly as one that happened.

What the public lists show on a given day, in November 2026

FDA and the European Medicines Agency each publish a list that anyone can read. FDA's data, through openFDA, held 1,153 rows marked Current on November 2, 2026. Each row is one package, so one shortage can fill many rows, and openFDA warns that it has not validated its data.

By our count of every Current row, they cover 69 generic product names, and 820 of them, or 71%, are injections; the count leaves out rows marked resolved or to be discontinued.7 EMA's catalog, generated on November 3, 2026, lists 27 ongoing shortages, 53 resolved and 5 discontinued medicines (our count of its export). It holds only shortages EMA has assessed, and EMA says it is not a full overview of EU shortages.8,3

These lines repeat public lists on the dates shown and say nothing about any firm's conduct. A listing can change on any day.

FDA section 506C: who must notify, about which medicines, and by when

In shortThe manufacturer or applicant of a prescription drug or biologic that is life-supporting, life-sustaining, or for a debilitating disease must tell FDA about a permanent discontinuance, or an interruption likely to cause a meaningful disruption in US supply. Notice is due six months ahead. If that could not be foreseen, it is due as soon as practicable and, for a finished product, no later than five business days after the event.

Section 506C of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 356c, is the statute. FDA's 2015 final rule put it into 21 CFR 314.81(b)(3)(iii) for drugs, 21 CFR 600.82 for biologics and 21 CFR 310.306 for drugs marketed without an approved application.9,1,10,2 The law reached its present shape in two steps: the FDA Safety and Innovation Act (July 9, 2012) and the CARES Act (March 27, 2020, in effect September 23, 2020), which added active ingredients, associated devices and redundancy plans.2,4

The clocks for a finished product and for an active ingredient differ

Counting five business days on a real calendar

Say a supplier's reactor shuts down on Friday, October 2, 2026. The first business day after it is Monday, October 5, so the fifth is Friday, October 9. Saturday and Sunday do not count.

The company may hear of it a day later, as a force majeure email on October 3. The text of the rule counts from when the event "occurs", with no allowance for how long the news takes to travel, which is why FDA's draft tells applicants to set up a process with suppliers so they get timely information.1,2 Build your internal date from the event, and treat any business day you lose to an unread mailbox as a day gone.

Failing to notify means a public letter, and FDA has sent few of them

If a firm misses the duty, FDA must send it a letter. The firm has 30 calendar days to explain and supply the information, and within 45 calendar days FDA posts the letter and any response, unless FDA finds the letter was issued in error or the firm had a reasonable basis.9,1

FDA has issued 11 such letters since 2014, and none in 2024 or 2025, and its page lists the letters with the firms' replies.4,11 The section's force lies in that public record and in losing FDA's help: a late notice leaves the agency less time to expedite a supplement or an inspection under section 506C(g).9,4

Section 506C(j) also asks for a plan you keep ready

Since the CARES Act, each maker of a covered drug, its API or an associated device must develop, maintain and, as appropriate, implement a redundancy plan that identifies and evaluates risks to supply for each establishment where the drug or its API is made. FDA may inspect and copy it.9 FDA's guidance on these plans has been a draft since May 2022.12 The redundancy plan is your forward-looking view of where supply could fail, and an early warning system is what tells you it has started to.

The meaningful disruption test sits well below a stock-out

In shortA meaningful disruption is a change in production reasonably likely to reduce a firm's own supply by more than a negligible amount and affect its ability to fill orders or meet expected demand. Waiting for a projected zero sets the bar too high. FDA wants to hear before you miss an order, and if you are unsure it urges you to file.

The definition has one carve-out: interruptions due to matters such as routine maintenance or insignificant changes in manufacturing, as long as the manufacturer expects to resume in a short period.1 Everything else that meets the test counts, whatever your market share, however many competitors could fill the gap, and however much product remains in distribution.2 The 2015 final rule says an applicant need not predict the market-wide effect of its interruption, and FDA's draft repeats it.2

Three lines in the draft change how a warning process should be set up. FDA should not first learn of a disruption when a firm cannot fill an order. If you are considering an action that may lead to a disruption, such as holding production to investigate a quality issue, FDA asks you to notify it immediately. And although a sudden demand spike with no manufacturing interruption falls outside the requirement, FDA asks you to report it anyway.2 These are recommendations in a draft, with no force of law, and they tell you how the people reading your notice think.

A late notice, step by step, at a fictional drug maker

Picture Cobbleford Pharma, a fictional maker of a sterile injectable that treats a debilitating condition. On March 2, its QA team holds three batches for a particle investigation. Its supply planner sees six weeks of stock and nobody speaks to regulatory affairs, because six weeks feels like plenty. On April 6 the investigation widens. On April 14 a wholesaler's order goes unfilled, and only then does regulatory affairs write to FDA.

Read against the text, the firm had a production change likely to affect its ability to fill orders by early March at the latest. FDA's draft had asked it to notify immediately when considering such a hold, and in any case before missing an order.2 The six weeks of stock was a reason to feel calm, and it had no bearing on the test. A process built around a weekly cover number alone will repeat that mistake, because cover stays high well after the legal question has been raised.

What FDA recommends on top of the minimum notice

The minimum is five or six facts. FDA's draft lists more that it finds useful, and you may send them later: they include whether the disruption is avoidable, the underlying root cause, the estimated start date, market share, historic monthly sales, whether the product is made on several lines or sites, current inventory, the date the last batch was or will be released, how long supply will last, any reserve and whether allocation is possible, whether a redundancy plan exists, and what you have told customers.

"Manufacturing delay" alone is called out as too thin.2 FDA also recommends updates about every two weeks until the situation is resolved, even if nothing has changed.2 Other reports do not count: a field alert report or a marketing status report is no substitute.2

EU shortage reporting: Article 23a, national rules and the European Shortages Monitoring Platform

In shortEvery EU holder tells the national regulator, under national rules that vary. Holders of centrally authorized medicines also report to EMA through the ESMP, as soon as they become aware of a potential or actual shortage, and have had to since February 2, 2025. Nationally authorized medicines enter the ESMP only in a crisis or a preparedness action. Two months' notice is the expected minimum, and most notices to EMA come on or after the start date.

Three layers apply at once. The Directive on medicinal products, 2001/83/EC, says in Article 81 that holders should ensure appropriate and continued supply, within the limits of their responsibilities, and in Article 23a that a holder must notify a member state if a product ceases to be placed on its market, temporarily or permanently, other than in exceptional circumstances no less than two months before.13 National laws add to that. Regulation (EU) 2022/123 adds the European platform.14

The Directive's wording leaves room for argument. The European Commission reads Article 23a as covering shortages, while some member states say it does not refer specifically to them, and 21 of 31 national regulators reported a separate national requirement in a 2022 survey.15 Almost all member states use their own definitions.15

The shared definition, in Regulation 2022/123 and quoted by EMA, is a situation in which supply of an authorized medicine does not meet demand at a national level, whatever the cause.3 The 2019 guidance from EMA and the Heads of Medicines Agencies (HMA), the network of national regulators, asks holders to report every current and anticipated shortage, regardless of the medicine's clinical importance or available alternatives.13

EMA's first functions for routine reporting went live on November 28, 2024, the full set on January 29, 2025, and the transition ended on February 2, 2025.16,3 Reporting works through a template or machine-to-machine.17 Each holder had to name an industry single point of contact, or i-SPOC, by September 2, 2022.18 Your own national duties carry on beside all this: EMA says so twice in one FAQ.3

"Potential shortage" has no harmonized EU definition yet. EMA's working description is plain: if a holder foresees the possibility of a shortage of a centrally authorized medicine in a particular market, it should report it. A working party is still discussing a definition.3 So the question to put to regulatory affairs is whether you foresee the possibility, which is a lower bar than whether a stock-out remains after your plan.

What national shortage rules ask, in six EU countries

The European Court of Auditors' examples, Figure 5, based on the CHESSMEN joint action.15 Check each country's current text before relying on it.

How late the EU's notices actually arrive

The European Court of Auditors looked at timeliness and found that most shortages were not notified two months ahead. For notifications to EMA, 55.9% came on or after the start date.15 It also noted shortages never notified at all, and that this leaves EMA without timely, complete and comparable information.15 EMA has no penalty to apply: its FAQ says there are currently no penalties for late reporting.3 National regulators can have them, and 18 of 30 EEA countries provide for sanctions, of which 8 have applied them.15

Shortage plans on the way: the EU pharma package, the Critical Medicines Act and rules elsewhere

In shortNeither EU law has passed. The Council's text of the pharmaceutical regulation sets six months' notice of a temporary disruption of more than two weeks and requires a shortage prevention plan for every prescription medicine, handed over within two days of a request. It would apply six months after entry into force, much sooner than the rest of the package. EMA is already telling companies to prepare.

The Council adopted its first-reading position on the pharmaceutical package on September 28, 2026, and Parliament's file reads "Awaiting Parliament's second reading", with no final act.19,20 The text can still change. Readers should note one detail that most summaries miss: while the regulation generally applies 24 months after entry into force, the Council text applies Articles 120 to 132, the shortage chapter, six months after entry into force.19 EMA's guidance page tells holders to be ready before a legal deadline "expected from mid-2027".18

EMA and the national regulators have already published the means. The prevention plan guidance, EMA/160238/2026, dated July 17, 2026, says plans will not be routinely filed, may be grouped by common supply chain, and may form part of the annual product quality review.21 The mitigation plan guidance, from September 2024, says companies should keep a record of root causes and measures after each shortage ends.23

ICH's revised quality risk management guideline, Q9(R1), added a section in January 2023 tying risk work to product availability, on the view that quality and manufacturing issues are a significant cause of shortages.24

The Critical Medicines Act is a separate file, aimed more at where medicines are made and how they are bought. Negotiators reached a provisional agreement on May 12, 2026, member states' ambassadors in Coreper endorsed it on June 30, and Parliament's public health committee approved it on July 14. As of November 3, 2026 it has no final act.25,26 Treat it as coming, and check for publication.

The Union list of critical medicines, version 2.1 revision 1, was last updated on January 19, 2026, and EMA says holders' further duties for listed products will come through the new legislation.27

The same duty in the United Kingdom and Canada

Volume gives a sense of the workload. UK companies filed 989 notifications in 2021, 1,608 in 2022 and 1,629 in 2023, and 1,013 in the first half of 2024, counting both potential and confirmed issues.28

Which supply indicators warn of a shortage first: holds, delay notices, shipment exceptions and demand

In shortManufacturing and quality problems lead every published cause list: 62% of FDA's 163 sampled drugs, 50.6% of 83,266 EU notifications. A shortage rarely announces itself in one place. Its warnings sit in the planning export, the quality system, a shared mailbox and a shipment feed, and the most useful one is often an email.

FDA's task force looked at 163 drugs that went into shortage between 2013 and 2017, and 62% did so after supply disruptions tied to manufacturing or product quality problems.30 National regulators analyzed 83,266 EU notifications from 24 countries for 2022 and 2023 and put manufacturing issues at 50.6%, with quality issues counted separately at 2.6%.15 The two studies sort causes into different categories, so their percentages cannot be compared or subtracted.

Many US shortages come with no stated reason. In the ASHP and University of Utah data for 2025, 59% of shortages had a cause that was unknown or not given.6 A buyer of your medicine often cannot tell why, and neither can a regulator unless you say so.

Where each supply warning lives, and who usually sees it first

One common source of trouble spreads beyond a single product. EMA's guidance gives the example of a single manufacturer contracted to make products or active substances for several holders, where one manufacturing issue reaches well past one product, and of a general issue such as a temperature excursion at a wholesaler touching more than one medicine.13 A warning process has to ask "what else came from there?" every time.

Weeks of cover and stock-out dates, worked through on 16 weeks of a German pen

In shortStart with stock on hand. For each coming week add receipts you can rely on and subtract demand. The first week below your safety stock is the warning, the first below zero is the stock-out, and stock divided by that week's demand is cover. The arithmetic takes minutes. The work is deciding which receipts you can still rely on.

Here is the fictional case with every figure, so you can follow the steps. The pen sells 3,100 units a week in Germany. Safety stock is two weeks of forward demand: 2 × 3,100 = 6,200 pens. A regional tender adds 18% from November 2: 3,100 × 18% is about 560, so demand becomes 3,660 a week. On hand on October 7 are 19,800 pens.

The first step takes out what you cannot count. Lot VLT-P-2611, 6,000 pens, is on QA hold, and its receipt moves to December 7 as 5,400 pens after the investigation. Shipment SH-77421, 3,800 pens, is quarantined after its logger read 9.4 °C for 47 minutes, so it counts as zero until QA decides. The tender adds 560 a week.

Then the delay notice moves lot 2614, 6,000 pens, from a November 20 ship date to December 14. Add the four: 6,000 + 6,000 + 3,800 + 2,800 (the tender's first five weeks at 560) = 18,600 pens short against plan.

Now read the line. Stock first drops under 6,200 in the week of November 16 (5,520). It first goes below zero in the week of November 30 (−1,800). Cover at that low point is −1,800 ÷ 3,660, or −0.5 weeks. From October 7, November 30 is 54 days, or 7.7 weeks.

The plan is the same arithmetic again with different receipts. Moving 4,200 pens from two other countries adds them in the week of November 2. A faster QA release brings 5,400 pens to November 16 from December 7. Air freight brings lot 2614 to the week of December 7. Stock now stays above zero and above safety stock, with its lowest point 6,480 pens on December 14, or 6,480 ÷ 3,660 = 1.8 weeks of cover.

Decisions the projection cannot make for you

Who decides on a shortage plan, and who signs the FDA or EU notification

In shortTwo decisions, two owners. Supply decides what to do about the gap. Regulatory affairs decides whether the law requires a notice, and it files. Neither FDA nor the EU names a job title: FDA holds the applicant solely responsible, and the EU holds the marketing authorization holder responsible through its single point of contact. Write down who signs what before the first alert.

FDA's draft says the applicant alone is responsible, whether it makes the product or a contractor does.2 The rule asks for electronic notice in a format FDA can process and sets no signatory.1 In the EU the marketing authorization holder is the responsible party, and its registered i-SPOC is the person EMA deals with.3,18 Inside a company that usually splits as shown below. No law sets this split. It is a common pattern, and your own procedures decide.

Mitigation moves a supply team can choose, and what each one costs

FDA's list of its own tools hints at what companies can do, including reviewing expiration date extensions and expediting review of a new source.4 In a company's own hands, the usual options are below. EMA's good practice paper adds a warning: stockpiling disrupts the supply chain, so use fair distribution and avoid quiet hoarding.22 FDA defines allocation as limiting the quantity distributed to customers to extend the life of supply.2

The duty to notify can stand even with a mitigation plan in place. FDA's test looks at the likely effect of a production change on your own supply, and the EU's looks at what you foresee. A solid plan is useful content for the notice. If regulatory affairs concludes no notice is owed, write down why, because that reasoning is what an inspector will ask about.

Seven ways drug makers find a shortage too late or file the notice late

In shortThe failures are mostly ordinary: a supplier's email nobody connected, held stock still in the forecast, a reason written as "manufacturing delay". The regulators have written about several of them, and each can be tested with a look through last quarter's records.

Why US drug shortages so often have no stated cause

Public detail is thin, so customers and competitors plan blind, and most of the facts sit in manufacturers' own records. By our count, FDA's data fills in a reason on only 406 of the 1,153 current rows.7 A company that knows why it is short can tell a regulator what is happening, and FDA's draft asks it to go beyond a recital of broad categories.2

What the shape of the market makes worse

The medicines most exposed to this are often old and cheap. Of FDA's 163 sampled drugs, 63% were sterile injectables and 67% had a generic version, with a median of almost 35 years since first approval and a median price of $8.73 per unit in the year before the shortage.30

USP reports that 71% of drugs in shortage at the end of 2025 were sterile injectables.5 In the ASHP data, 48% of new shortages in 2026 involve sole-source products.6 For a single-source product, "your own supply" and "the market's supply" are the same thing, so a late warning leaves customers nowhere to turn.

What AI can do for drug shortage prediction, and what regulators expect of it

In shortReading an email and rebuilding a projection are jobs software does well, because a person can check each result against its source. Predicting market shortages from outside data is much less proven. Regulators have no shortage-specific AI rule. The draft EU GMP Annex 22 would bar large language models from critical GMP uses, so keep the batch release decision away from them, and a person signs what goes to a regulator.

"Drug shortage prediction" covers two different problems. One is forecasting whether a medicine will be short nationally, from public or pharmacy data. The published work here is modest. A Canadian study on sales from 22 pharmacies reached 69% accuracy across four shortage classes one month ahead, with a kappa, a measure of agreement beyond chance, of 0.44, and correctly predicted 59% of the most impactful shortages, with no manufacturer inventory data.31

An informal single-author analysis of about 3,000 drugs in October 2026 found machine learning did not clearly beat a simple score based on dosage form and similar features, and it warned against reading those associations as forecasts.32 We found no peer-reviewed lead-time result for a system that reads a manufacturer's own records.

The other problem is what this guide describes: a manufacturer using its own records. Here most of the answer is arithmetic on known receipts and known demand. Software adds speed and reach: reading a delay notice the minute it lands, matching a lot to the markets that depend on it, and rebuilding every projection touched. A person can verify each step. Measure it by replaying your own past events through the tool.

What stays with people when supply warnings are automated

How supply teams run shortage monitoring today, and where an estimated 54 hours go

In shortMost teams use a weekly planning meeting, a spreadsheet and a shared mailbox, with planning and quality systems each holding part of the picture. We found no published benchmark for how long this takes. Our own working estimate is about 54 hours from notice to signed plan, about 24 of them waiting. Time your own last three cases and replace our estimate.

Continuity lead, planner, market lead, QA, risk head and regulatory affairs: who touches a shortage

From a CMO's email to a signed plan, by hand

Four ways companies organize shortage monitoring

October 7: a 9:18 am delay notice moves the German Veltrimab pen from no stock-out to a stock-out on November 30

In shortLena Ortiz, supply continuity lead for Europe and International, opens the shortage radar with one unread notice from the contract fill-finisher. One click reads it, matches lot 2614 to the German pack, and rebuilds 16 weeks of stock. The risk score goes from 61 to 86, and the drivers each cite the record behind them. Six minutes later Lena signs a three-move plan.

1

The shortage radar, with one supplier notice still unread

Each sector is a product and each dot a market. The closer a dot sits to the center, the fewer weeks remain before the projected stock-out, and the dotted outer ring holds alerts with no stock-out inside 16 weeks. The 5:42 am sweep has placed all 48 product-markets.

The German pen is already open as alert A-2611, risk 61: below safety stock on November 16, lowest cover 0.6 weeks on December 14, no stock-out. Three drivers, ranked by weeks of cover lost: the QA hold (−1.7), the quarantined shipment (−1.1) and the tender (−0.8). Above the radar, a notice from Halvorsen Fill-Finish about lot 2614 is marked as not read yet.

2

"Read it now": the notice is read on screen and the dot moves

The notice reader reads the email and quotes the passage it relies on: the fill of lot 2614 moves from October 26 to November 16 and the ship date from November 20 to December 14. That is 6,000 pens three weeks late. It matches lot 2614 to the German pack, and the risk scorer rebuilds the projection with the receipt moved.

The result appears in place: runs out November 30, in 54 days, 7.7 weeks if nothing is done. The score rises to 86, and the German dot moves inward to the 8-week ring and turns red. The delay becomes driver 1, marked new at 9:18.

3

The supplier's own words, highlighted

Every driver carries a citation. Opening the delay driver shows the email as a read-only copy, with the passage the agents cite highlighted. The second highlight matters too: lot 2614 can ship on December 4 if air freight is acceptable, so the way out is already in the source.

4

Four drivers on the same six weeks, each with weeks of cover lost

The alert opens on the projection. Projected stock-out November 30, lowest cover −0.5 weeks, first week under safety stock November 16. The four drivers each show what they take: the delay and the QA hold on lot VLT-P-2611 at −1.7 weeks each, the quarantined shipment SH-77421 at −1.1 weeks, and the tender at −0.8 weeks. That adds up to 18,600 pens short against plan, worked through in section 08.

On the right sit the six records behind it all: the planning export row, the deviation, the delay notice, the shipment exception, the demand update and the critical product list.

5

Six options drafted, three recommended, and the stock-out gone

The mitigation planner drafts options from the network, each with an owner, a cost and the weeks it buys. The three recommended: move 4,200 pens from the Netherlands and Austria (+1.2 weeks, €14,800 freight), QA priority on the deviation to release 5,400 pens on November 16 instead of December 7 (+1.5 weeks, no direct cost), and air-freight lot 2614 (+1.7 weeks, €22,500).

With all three, the stock-out goes from November 30 to none and lowest cover from −0.5 to 1.8 weeks on December 14. Austria would give 24% of its buffer, so the screen flags a second approval for Omar Haddad, head of supply-chain risk.

6

Lena confirms the risk and signs the plan

The confirmation shows the alert, the three moves with their owners and the result: no stock-out, lowest 1.8 weeks. Lena chooses the meaning of her signature, "I confirm this supply risk and approve the plan", and enters her password. The second approval request goes to Omar Haddad with her signature, at 9:24 am.

7

Tasks go to their owners, and the alert moves to Mitigating

The decision is recorded and three tasks go out: Priya Ranvelle for the reallocation, Dana Okafor for the QA priority, Sam Patel for the air freight. The second approval waits with Omar Haddad. The alert will stay in Mitigating until cover holds above safety stock for four weeks.

The last line says no stock-out is projected, so the authority notice is not needed, and the rationale is recorded. See the next section for what to make of that line.

The FDA 506C notice and the EU shortage report, drafted from cited records and filed by regulatory affairs

In shortEach alert has an authority notice tab. For a US alert it counts business days and drafts the 506C fields. For an EU alert it drafts the national and ESMP report. The notice writer drafts, Hannah Weiss in regulatory affairs reviews and files, and no agent writes to a regulator. Two screens need a careful reading against the rules in Part A, and the captions say so.

1

Meanwhile in the US: the Talvoren vial with two business days left

Sam Patel's alert A-2609, risk 78. On October 3 at 8:02 am, Kestrel Fine Chemicals sent a force majeure notice: an unplanned shutdown of reactor R-4 on October 2 delays API lots K-77 to K-79 by about six weeks, and the supplier does not expect more than eight. US stock of Talvoren 100 mg/10 mL vials runs out on December 21 if nothing is done.

The tab counts five business days from October 2, so due October 9, and on October 7 that leaves two. The notice writer fills the fields from the cited records: drug, applicant, type, date, reason, expected duration, whether a meaningful disruption is likely, actions and contact.

2

The EU report for the German pen, before the plan

Before Lena signs, the German alert's tab shows "Now: report as soon as a shortage is likely", and the draft says yes, a shortage is likely: start November 30 if nothing is done, supply back from December 14. Medicine, holder, member state and the four reasons each cite their record. The recipients line reads "European Shortages Monitoring Platform (ESMP) · national authority, Germany".

3

After the plan: "No notice needed while the plan holds"

Once the approved plan removes the projected stock-out, the tab changes. It shows "No notice needed while the plan holds", Its "Shortage likely?" line now reads "Not with the approved actions", the report is kept as a draft with that rationale, and the mitigation lines fill in.

Read this screen as a recommendation that regulatory affairs then tests. EMA asks holders to report a potential shortage of a centrally authorized medicine when they foresee the possibility of one.3 Germany's rule, in the European Court of Auditors' summary, is immediate notification if a shortage could disrupt patient care.15 A plan that depends on a QA release and an air freight booking is a reason to file early, with the plan attached, and update. Our view is that most teams would file a potential shortage here.

What the US screen's meaningful disruption question tests, and what the rule tests

The screen asks "Is a meaningful disruption likely?" and answers from the projected stock-out. FDA's test is lower: a change reasonably likely to reduce your own supply by more than a negligible amount and affect your ability to fill orders or meet expected demand.1 For Talvoren, a supplier outage that removes three API lots and 17,200 vials against plan meets that test whatever the stock-out date, and the guide's advice is to file. Ask any vendor, including us, to show you how its rule for the question can be set to your company's reading.

The risk register, the supply indicators feed, the continuity dashboard and the alert rules

In shortFour more screens carry the work between alerts. The register ranks open alerts and keeps the decision log. The supply indicators screen shows everything read, matched and linked. The dashboard tracks warning time and decisions. The settings hold your alert windows, sources and approvers.

Six agents read and draft; the continuity lead, a second approver, QA and regulatory affairs decide

In shortEach agent has one job and stated limits. None of them edits the plan, releases stock, contacts a supplier or writes to a regulator. People confirm or dismiss every alert, approve every plan, give a second approval on any move over a fifth of a market's buffer, and file every notice.

Who signs at each step of a shortage alert

The records support the controls an inspector expects of electronic records where a predicate rule applies: attributable entries, audit trails and authority checks.37,38 They are controls that support your compliance; your own validation and procedures decide whether you meet it. Botminds' own security is audited under SOC 2 Type II, and its information security is managed to ISO 27001.

What Drug Shortage Early Warning reads from your planning, quality and logistics systems, and what it gives back

In shortIt reads what your supply already runs on: the planning export, the quality system, the supply mailbox, the shipment exception feed and your critical product list. It gives back a ranked risk register with cited drivers, alerts with drafted plans and notices, a weekly dashboard and a decision log. Your systems stay the record.

The systems a shortage warning tool connects to, by category

The warning time and confirmation rate Drug Shortage Early Warning is designed to reach

In shortTwo design targets, each to be measured in your own live use: a median of 7.4 weeks of warning before a projected stock-out, against a goal of six or more, and 82% of alerts confirmed by planners, with the rest dismissed with a reason. Neither is a result from a customer. Measure them on a replay of your own last quarter before you rely on them.

The time a person still spends is the time that matters: deciding the plan, signing, and deciding on the notice. The waiting time is where the estimate moves most, and it is the easiest to measure: the gap between an email's arrival and the change in your plan.

What a shortage found too late costs a drug maker, and how to count your own in a week

In shortNo public source puts a price on a manufacturer's stock-out, so that figure has to come from your own records. What is published shows the scale around you: most EU notices arrive late, FDA hears about well over a thousand potential shortages a year, and US hospitals spent $894 million in labor managing shortages in 2023. Your own cost lies in lost sales, tender terms, freight, and the regulator's patience.

That hospital time is your customers' cost, and it shapes how they judge suppliers in the next tender. Your own costs sit in different places, and most of them are already in your systems.

Counting the cost of late shortage warnings in your own records

Shortage costs no return calculator counts

Sizing the return on earlier shortage warnings: team hours, stock-outs avoided and freight not needed

In shortThree levers carry most of the value: fewer hours turning each supply event into a decision, fewer events that become stock-outs because they are seen weeks earlier, and less premium freight because options are chosen before only the fastest remains. A fourth, notices filed on time, protects you and is hard to price, so it stays out of the total. Every default below is a placeholder for your own number.

Formulas: hours freed = events × max(0, hours today − hours with automation); hours valued = that × hourly cost; stock-outs avoided = events × max(0, share today − share with warning) ÷ 100; valued = that × cost of one stock-out; freight = events × premium freight share ÷ 100 × freight saved. With the defaults: 2,880 hours, $259,200; 3.6 stock-outs avoided (the calculator rounds to 4), $1,440,000; freight $360,000; total $2,059,200 a year. The stock-out line carries most of the value and the most doubt, so replace it with your own history first.

Is your supply team ready to automate shortage monitoring? Eight scored questions and one to reflect on

In shortScore each question 0 to 2. The questions test what software needs from you: a critical list, readable records, named owners, a written rule for notices and a way to measure. A low score is useful: it tells you what to fix first, and most of it needs no software.

What a low, middle or high shortage readiness score means

What to ask a drug shortage early warning vendor about notices, projections, the 506C clock and who signs

In shortAsk for proof on your own records. Many products watch the market from outside, and some forecast from public lists. Find out whether a tool reads your own quality records and supplier mail, how it rebuilds a projection, how it treats held stock, and how it frames the notice question. Ask us the same.

A 10-week shortage warning pilot: replay last quarter on your own records, then run Tier 1 live

In shortStart with the past. Pick a quarter with real supply events, load its planning exports, quality records and supplier mail, and see when the warnings would have come compared with when your team found out. Then run your Tier 1 products live in one region, in parallel with your current process, with people deciding.

Five numbers that tell you whether shortage warnings arrive earlier

506C deadlines, meaningful disruption, the ESMP and shortage prediction: common questions

In shortCommon questions about drug shortage notification and early warning, each answered on its own.